<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422419</url>
  </required_header>
  <id_info>
    <org_study_id>IICT2017_PROGRESS</org_study_id>
    <nct_id>NCT03422419</nct_id>
  </id_info>
  <brief_title>TIPS or Anticoagulation in Portal Vein Thrombosis</brief_title>
  <acronym>PROGRESS</acronym>
  <official_title>An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing
      anticoagulation, which is the currently most frequently used treatment, alone, versus
      transjugular intrahepatic portosystemic shunt (TIPS) combined with anticoagulation, in
      patients presenting with recent obstructive portal vein thrombosis (ROPVT). The rationale of
      this study is to significantly increase the proportion of patients that achieve a complete or
      partial recanalization of the portal vein. The intervention of this study consists in TIPS
      deployment and catheter based clot removal in addition to anticoagulation. The investigators
      retain that this intervention will increase the proportion of patients with an open portal
      vein from 38% with anticoagulation alone to 83% with anticoagulation and TIPS after 6 months.
      Both anticoagulant therapy and clot removal/TIPS are treatments that are currently available
      and accepted indications for the treatment of ROPVT. Anticoagulation will be performed with
      unfractioned heparin or low molecular weight heparin initially and with vitamin K antagonists
      in the long term. The investigators plan to collect blood for biobanking at the time of
      inclusion and after 6 months. Blood samples for a biobank will be collected.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of funding
  </why_stopped>
  <start_date type="Anticipated">August 1, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with complete recanalization of the portal vein&quot;.</measure>
    <time_frame>6 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Thrombosis Portal Vein</condition>
  <arm_group>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>The choice of the anticoagulant medication in terms of duration and dose will be determined by the treating physician.</description>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TIPS</intervention_name>
    <description>transjugular intrahepatic portosystemic shunt deployment</description>
    <arm_group_label>TIPS+Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Recent complete thrombosis of the extrahepatic portal vein either with or without the
             involvement of intrahepatic branches and with or without involvement of splenic vein
             and superior mesenteric vein

          2. Written informed consent

        Exclusion Criteria:

          1. Malignant Portal Vein thrombosis (neoplastic invasion)

          2. Intraabdominal malignancy

          3. Chronic diseases limiting life expectancy in the short term (6 months)

          4. Liver transplantation

          5. Unwillingness to participate

          6. Contraindications to TIPS (including past or present hepatic encephalopathy Grade â‰¥2)

          7. Child-Pugh-Turcotte score 11 or more points in patients with advanced chronic liver
             disease-
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea De Gottardi, Prof. Dr. med</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Inselspital, Berne</affiliation>
  </overall_official>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 30, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>October 30, 2018</last_update_submitted>
  <last_update_submitted_qc>October 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

